Evidence map›Paper›PMID 40877150›Full record

ArticleIn vivo (Athens, Greece)

Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study.

Mioko Matsuo, Mamoru Ito, Kenji Tsuchihashi, Hirofumi Ohmura, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Shogo Masuda, Takashi Nakagawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mioko MatsuoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; matsuo.mioko.202@m.kyushu-u.ac.jp.
Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kenji TsuchihashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hirofumi OhmuraDepartment of Hematology, Oncology and Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kazuki HashimotoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryunosuke KogoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masanobu SatoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shogo MasudaDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takashi NakagawaDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimRefractory differentiated thyroid carcinoma (DTC) and anaplastic thyroid carcinoma (ATC) are associated with poor prognoses. Molecularly targeted agents such as lenvatinib are expected to significantly improve outcomes. However, data from real-world settings remain limited. PATIENTS AND

methodsA retrospective analysis was conducted in 48 patients with thyroid carcinoma treated with lenvatinib at Kyushu University Hospital between April 2015 and October 2024. We compared overall survival (from time of treatment initiation to death, censoring, or data cutoff) and progression-free survival (from time of treatment initiation to tumor progression as confirmed by image examination) using Kaplan-Meier analysis. A subgroup analysis was also conducted for patients who had and had not received prior radioactive iodine (RAI) therapy.

resultsThe analysis included 29 female and 19 male cases. The histologic types were papillary thyroid carcinoma in 26 patients, follicular thyroid carcinoma in seven patients, and ATC in 15 patients. Of 33 DTC cases, RAI was not administered in nine cases. The median progression-free survival was 30 months for papillary thyroid carcinoma, 18 months for follicular thyroid carcinoma, and four months for ATC. The median progression-free survival for patients with DTC who received RAI therapy was 19 months, whereas that for patients with DTC without RAI therapy was 46 months. No significant difference was found between the two groups (

conclusionLenvatinib may be effective in patients with DTC in whom RAI treatment is not feasible in real-world settings.

Indexed as

Antineoplastic AgentsPhenylurea CompoundsQuinolinesThyroid NeoplasmsAdenocarcinoma, FollicularAdultAgedAged, 80 and overFemaleHumansIodine RadioisotopesKaplan-Meier EstimateMaleMiddle AgedPrognosisProtein Kinase InhibitorsAntineoplastic AgentsIodine RadioisotopeslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesanaplastic thyroid carcinomaDifferentiated thyroid carcinomalenvatinibreal-world datawithout RAI therapy

Identifiers

PMID40877150
PMCPMC12396069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.